We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondary Hyperparathyroidism (SHPT) (PACE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00823303
First Posted: January 15, 2009
Last Update Posted: August 7, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Henry Ford Hospital
Feinberg School of Medicine, Northwestern University
NorthShore University HealthSystem
Abbott
Information provided by (Responsible Party):
Daniel W. Coyne, Washington University School of Medicine
Results First Submitted: June 5, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Secondary Hyperparathyroidism
Chronic Kidney Disease
Interventions: Drug: Paricalcitol
Drug: Calcitriol

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Paricalcitol

titrated to achieve 40-60% PTH suppression

Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression

Calcitriol

titrated to achieve 40-60% PTH suppression

Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression


Participant Flow:   Overall Study
    Paricalcitol   Calcitriol
STARTED   54   56 
COMPLETED   45   45 
NOT COMPLETED   9   11 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Stage 3 and 4 CKD with SHPT, age >18, a stable dose of phosphate binder (if receiving a binder), estimated glomerular filtration rate (eGFR) of 15-59 mL/min using the abbreviated MDRD equation, PTH >120 pg/mL, albumin-corrected calcium >8.5 mg/dL and <10.0 mg/dL, phosphorus <4.6 mg/dL.

Reporting Groups
  Description
Paricalcitol

titrated to achieve 40-60% PTH suppression

Paricalcitol: 1 mcg daily, adjusted to achieve 40-60% PTH suppression

Calcitriol

titrated to achieve 40-60% PTH suppression

Calcitriol: 0.25 mcg daily, adjusted to achieve 40-60% PTH suppression

Total Total of all reporting groups

Baseline Measures
   Paricalcitol   Calcitriol   Total 
Overall Participants Analyzed 
[Units: Participants]
 54   56   110 
Age 
[Units: Years]
Mean (Standard Deviation)
 66.6  (13.2)   64.7  (12.6)   65.6  (12.9) 
Gender 
[Units: Participants]
     
Female   24   30   54 
Male   30   26   56 
Race (NIH/OMB) 
[Units: Participants]
     
American Indian or Alaska Native   0   0   0 
Asian   0   0   0 
Native Hawaiian or Other Pacific Islander   0   0   0 
Black or African American   33   41   74 
White   18   14   32 
More than one race   0   0   0 
Unknown or Not Reported   3   1   4 


  Outcome Measures

1.  Primary:   Confirmed Hypercalcemia   [ Time Frame: 24 week treatment period ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Daniel W. Coyne
Organization: Washington University School of Medicine
phone: 3143627211
e-mail: dcoyne@dom.wustl.edu


Publications of Results:

Responsible Party: Daniel W. Coyne, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00823303     History of Changes
Other Study ID Numbers: 22095
First Submitted: December 12, 2008
First Posted: January 15, 2009
Results First Submitted: June 5, 2014
Results First Posted: August 5, 2014
Last Update Posted: August 7, 2014